<DOC>
	<DOCNO>NCT00612742</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled , adaptive design , multi-center study long-term cardiovascular breast safety LibiGel treatment HSDD postmenopausal woman least two point cardiovascular risk clinical diagnosis Hypoactive Sexual Desire Disorder ( HSDD ) .</brief_summary>
	<brief_title>Safety Efficacy LibiGelÂ® Treatment Hypoactive Sexual Desire Disorder Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Postmenopausal female subject least 50 year age least two point cardiovascular risk clinical diagnosis HSDD . Subjects must require treatment antiandrogens , highdose oral injectable corticosteroid , tamoxifen selective estrogen receptor modulators , use androgen therapy within 2 month randomization , history estrogendependent neoplasia gynecologic cancer , history cancer kind past 10 year prior randomization , history malignant melanoma history invasive cancer time , screen mammogram finding require follow within 6 month randomization , history myocardial infarction , coronary revascularization stroke within 12 month randomization , medical condition associate predict survival le 3 year judgment Investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Cardiovascular event</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Menopause</keyword>
	<keyword>Hypoactive Sexual Desire Disorder</keyword>
</DOC>